AtonRa Partners Sells 146 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

AtonRa Partners cut its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 8.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,590 shares of the medical equipment provider’s stock after selling 146 shares during the quarter. AtonRa Partners’ holdings in Intuitive Surgical were worth $536,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in ISRG. WCM Investment Management LLC purchased a new stake in shares of Intuitive Surgical during the fourth quarter valued at $575,536,000. International Assets Investment Management LLC grew its stake in shares of Intuitive Surgical by 32,360.5% in the fourth quarter. International Assets Investment Management LLC now owns 686,865 shares of the medical equipment provider’s stock worth $231,721,000 after acquiring an additional 684,749 shares during the period. Alphinity Investment Management Pty Ltd raised its holdings in shares of Intuitive Surgical by 113.2% during the fourth quarter. Alphinity Investment Management Pty Ltd now owns 1,276,158 shares of the medical equipment provider’s stock valued at $430,525,000 after purchasing an additional 677,455 shares during the last quarter. J.P. Morgan Private Wealth Advisors LLC bought a new position in Intuitive Surgical during the third quarter valued at approximately $178,667,000. Finally, Quadrature Capital Ltd boosted its holdings in Intuitive Surgical by 466.2% in the third quarter. Quadrature Capital Ltd now owns 340,644 shares of the medical equipment provider’s stock worth $99,601,000 after purchasing an additional 280,480 shares during the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Intuitive Surgical Stock Down 0.3 %

ISRG stock traded down $1.19 during midday trading on Monday, hitting $374.14. The company’s stock had a trading volume of 983,060 shares, compared to its average volume of 1,649,463. Intuitive Surgical, Inc. has a 12 month low of $254.85 and a 12 month high of $403.76. The company has a 50 day moving average of $386.19 and a two-hundred day moving average of $346.74. The firm has a market capitalization of $132.71 billion, a price-to-earnings ratio of 67.53, a price-to-earnings-growth ratio of 4.85 and a beta of 1.36.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.10. The company had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. Intuitive Surgical’s quarterly revenue was up 11.5% on a year-over-year basis. During the same period last year, the company posted $1.00 earnings per share. On average, analysts anticipate that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current fiscal year.

Insider Transactions at Intuitive Surgical

In related news, President David J. Rosa sold 80,710 shares of the stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $389.28, for a total transaction of $31,418,788.80. Following the completion of the transaction, the president now directly owns 163,399 shares of the company’s stock, valued at $63,607,962.72. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, Director Alan J. Levy sold 2,000 shares of the business’s stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total value of $741,400.00. Following the sale, the director now directly owns 25,319 shares in the company, valued at approximately $9,385,753.30. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, President David J. Rosa sold 80,710 shares of the company’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $389.28, for a total transaction of $31,418,788.80. Following the sale, the president now owns 163,399 shares in the company, valued at $63,607,962.72. The disclosure for this sale can be found here. Over the last three months, insiders have sold 225,093 shares of company stock valued at $87,153,299. 0.80% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ISRG. Barclays raised their price target on Intuitive Surgical from $385.00 to $430.00 and gave the stock an “overweight” rating in a research note on Thursday, January 25th. Robert W. Baird cut their price target on Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a research note on Friday, April 19th. BTIG Research increased their price objective on shares of Intuitive Surgical from $412.00 to $421.00 and gave the stock a “buy” rating in a research note on Friday, April 19th. Jefferies Financial Group boosted their target price on shares of Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a research report on Friday, April 19th. Finally, Truist Financial lifted their price target on shares of Intuitive Surgical from $390.00 to $435.00 and gave the stock a “buy” rating in a research note on Wednesday, January 24th. Five analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $396.17.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.